ADVB advanbiomed.com: Net Margin

Advanced Biomed - graphic logo of issuer ADVB

Advanced Biomed Inc (ADVB) generates revenue from supplying liquid biopsy systems to clinics and hospitals. The net margin structure confirms financial stability, with the current figure standing at -6325.90. The company develops microfluidic platforms featuring AI-driven cell analysis for early screening. Business growth is driven by the successful commercialization of developments and the progress of clinical trials, rendering the asset independent of macroeconomic fluctuations.

advanbiomed.com (ADVB) - Return on Sales by Net Profit from 03/07/2025 to 11/19/2026

Comprehensive metric breakdowns and analytics for Advanced Biomed Inc. (ADVB)

- share price and expert price forecast:
- company stock capitalization data:
Summary company analytics:Advanced Biomed Inc - ADVB
Flagship merchandise of Advanced Biomed

The integration of ESG principles and the greening of biochemical processes at Advanced Biomed Inc (ADVB) directly impact the operational expenditure structure. The consolidated net profit margin reflects the portion of net income in every dollar of revenue after deducting all expenses. The compression of this metric on the chart signals that costs are outstripping revenues. A positive trend confirms the efficiency of resource management. This current price action determines the stability of the asset's market value.

Direct competitors

ONC: Net Sales Margin|Net Margin Halozyme Inc. (HALO)|Net Margin RevMed|Net Return on Sales AAPG (Ascentage Pharma Group)|Net Sales Margin CGON|UroGen Pharma - Net Return on Sales|Bicara Therapeutics - Return on Sales by Net Profit|Net Sales Margin Personalis Inc PSNL|Erasca Oncology - Net Sales Margin|Net Profit Rate DCTH (Delcath Corp)|YMAB: Net Sales Margin|AURA - Company Sales Margin|CADL (Candel Therapeutics Inc.) - Net Sales Margin|Net Return on Sales ARAY (Accuray)|Return on Sales by Net Profit SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Net Margin|Net Margin Citius Oncology, Inc. CTOR|HURA - Return on Sales by Net Profit|protaratx.com - Net Sales Margin|FATE - Net Sales Margin|WHWK: Net Sales Margin|TScan Therapeutics (TCRX) - Net Sales Margin|Net Margin Champions Oncology|Net Margin XBIT|Net Sales Margin CVM|Return on Sales by Net Profit OS Therapies Inc. OSTX|Net Margin Radiopharm Theranostics Limited RADX|artivabio.com (ARTV) - Net Margin|ANL - Net Margin|Net Margin verupharma.com|TPST: Net Sales Margin|XLO - Company Sales Margin|Net Margin Renovaro|Net Sales Margin muraloncology.com|Net Sales Margin KAPA|Company Sales Margin OnKure Therapeutics, Inc.|Net Sales Margin GDTC (w2.cytomed.sg)|CRIS - Return on Sales by Net Profit|Apollomics - Net Sales Margin|Tharimmune Corp (THAR) - Return on Sales by Net Profit|GNPX: Net Sales Margin|CLDI (Calidi Biotherapeutics Inc.) - Net Margin|Net Margin Sunshine Biopharma, Inc.|Net Sales Margin xeneticbio.com|Net Margin Salarius (SLRX)|Return on Sales by Net Profit Purple Biotech PPBT|Net Margin American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Net Margin|Checkpoint Therapeutics Inc. - Net Sales Margin|Net Profit Rate ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Return on Sales by Net Profit|Ikena Oncology, Inc. - Net Profit Rate|Return on Sales by Net Profit NTBL|VIRX: Net Profit Rate|Net Margin MorphoSys Corporation (MOR)|NAYA - Net Margin|Net Sales Margin AAPGV (Ascentage)